INDEX

Volume 35 1980

A

A Trade Association View of the FDA Food Inspection Programs. Mar., p. 170.

Abrams, William B.—FDA Disqualification of a Clinical Investigator. Sept., p. 498.

Actions in the Courts. Sept., p. 502.

Adams, Leland J., Jr.—Cosmetic or Drug? FDA's OTC Drug Review Program Provides Some Answers and Raises New Questions. Feb., p. 96.

Advertising
Restraints on Use of the Term "Natural" in Labeling of Foods. July, p. 404.

Advisory Committees
Medical Devices: Past and Future of FDA's Advisory Committees. Oct., p. 604.

Anastasio, Elisa L.—Restraints on Use of the Term "Natural" in Advertising and Labeling of Foods, Drugs and Cosmetics. July, p. 424.

Austern, H. Thomas—Food Regulation and the New Technology: The Evolving Governmental Process. Jan., p. 15.

B

Becker, Robert H.—Sensitivity of Method—Legal Implications. June, p. 355.

Belair, Robert R.—Drug Use Research: Privacy Pitfalls. Apr., p. 235.

Berkowitz, Kenneth P.—Recent Developments in Food and Drug Law 1979—1980. Sept., p. 527.

Biologics
New Legislation and Government Regulation. June, p. 385.

BRH and Medical Device Regulation. May, p. 314.

Britain, Robert G.—BRH and Medical Device Regulation. May, p. 314.

Bureau of Radiological Health
Medical Device Regulation. May, p. 314.

Burg, Laurie—A Trade Association View of the FDA Food Inspection Programs. Mar., p. 170.

C

Canada
Evolution of Drug Regulation Within the Health Protection Branch. Aug., p. 451.

Canada: Evolution of Drug Regulation Within the Health Protection Branch. Aug., p. 451.

Carcinogens

Sensitivity of Method—A Wave of the Future. June, p. 342.

Sensitivity of Method—Legal Implications. June, p. 355.

Carey, Charles J.—Proposal for a Realistic Improvement in the Labeling of Processed Foods. Mar., p. 143.

The Changing Philosophy of OTC Review. Dec., p. 673.

Characterization of Medical Devices. Oct., p. 588.

Characterization of Medical Devices—Another View. Oct., p. 594.

Classification

Drug Enforcement Administration: Scheduling Policy. Dec., p. 691.

Clinical Investigators

FDA Disqualification. Sept., p. 498.

The New Regulations. Sept., p. 493.

Regulation. July, p. 415.

The Role of FDA Disqualification in Protecting Human Research Subjects. Sept., p. 484.

Cole, Michael F.—History of Premarket Approval Provisions of the Device Amendments. Oct., p. 568.

Comments on Recent Cases. Feb., p. 122.

Comments on Recent Cases. Aug., p. 462.

Completing the OTC Process. Dec., p. 698.

Condon, William J.—Product Liability —1979. July, p. 404.

Confidentiality

Premarket Approval of New Medical Devices. Oct., p. 576.

The Constitutionality of Warrantless Inspections by the Food and Drug Administration. Jan., p. 25.

Controlled Substances Act

Therapeutic Use of Marihuana and Heroin: The Legal Framework. Feb., p. 68.

Cooper, Iver P.—Comments on Recent Cases. Feb., p. 122.

Cooper, Iver P. and Weitzman, Stephen A.—Comments on Recent Cases. Aug., p. 462.

Cooper, Richard M.—Regulatory Reform? Apr., p. 193.

Cooper, Richard M.—Therapeutic Use of Marihuana and Heroin: The Legal Framework. Feb., p. 68.

Corporate Counsel

Role in Defense of FDA Court Actions. June, p. 370.

Cosmetic or Drug? FDA's OTC Drug Review Program Provides Some Answers and Raises New Questions. Feb., p. 98.

Cosmetic GMPs

A Legal Perspective. Nov., p. 651.

FDA Technical Update. June, p. 335.

Industry Concerns Arising from Recent FDA Activities. June, p. 392.

OTC Drug Review and Labeling. June, p. 325.

When Is a Cosmetic Also a Drug—What You Need to Know, and Why. Aug., p. 467.

Cosmetics

Cosmetic or Drug? FDA's OTC Drug Review Program Provides Some Answers and Raises New Questions. Feb., p. 98.

Cosmetics—FDA Technical Update. June, p. 335.

Cosmetic Industry Concerns Arising from Recent FDA Activities. June, p. 392.

Cosmetic Ingredients and Labeling in the OTC Drug Review. June, p. 325.

Court Cases

Comments on the NADA Process and "Imitation" Food Labeling. Aug., p. 462.

Inspections. Sept., p. 502.

Product Liability—1979. July, p. 404.

Role of Corporate Counsel. June, p. 370.

Critical Devices

Is a New Definition Necessary? June, p. 376.

Critical Devices: Do We Need a New Definition? June, p. 376.

D

Definitions

Is a New One Necessary for Critical Devices? June, p. 376.

DESI Review

Old Drug/New Drug: The Marketplace Influences the Law. Apr., p. 221.

Dixler, Daniel S., Ph.D.—The Impact of Sensitivity of Method on Food Regulation. June, p. 349.

Doherty, George M.—The Inspections Process. Oct., p. 555.

Drug Enforcement Administration

Scheduling Policy and Classification. Dec., p. 691.

Therapeutic Use of Marihuana and Heroin: The Legal Framework. Feb., p. 68.

The Drug Enforcement Administration: Scheduling Policy and Classification. Dec., p. 691.

Drug Legislation

The U. S. Food and Drug Law: How It Came; How It Works. Mar., p. 132.

Drug Safety

Human Pharmaceuticals, Patents, and the FDA. Feb., p. 83.

Drug Use Research: Privacy Pitfalls. Apr., p. 235.

Drugs

Drug Use Research: Privacy Pitfalls. Apr., p. 235.

Old Drug/New Drug: The Marketplace Influences the Law. Apr., p. 221.

The OTC Drug Review—A Change in Direction. Mar., p. 179.

When Is a Cosmetic Also a Drug—What You Need to Know, and Why. Aug., p. 467.

E

Elengold, Mark.—Freedom of Information Policy at the FDA. Nov., p. 627.

Endries, Robert N.—The Regulation of Clinical Investigators. July, p. 415.

F

FDA

The Changing Philosophy of OTC Review. Dec., p. 673.

Characterization of Medical Devices. Oct., p. 588.

Characterization of Medical Devices —Another View. Oct., p. 594.

Completing the OTC Process. Dec., p. 698.

Cosmetic Industry Concerns Arising from Recent Agency Activities. June, p. 392.

Cosmetics—Technical Update. June, p. 335.

Disqualification of a Clinical Investigator. Sept., p. 498.

Effects of Substantive Rules. May, p. 270.

Freedom of Information Policy. Nov., p. 627.

How to Handle an FOI Problem. Dec., p. 668.

The Inspections Process. Oct., p. 555.

Preparing for Cosmetic GMP—A Legal Perspective. Nov., p. 651.

Standards-Setting Policy. May, p. 300.

Trade Secret Procedures and Standards. June, p. 362.

FDA and the Effects of Substantive Rules. May, p. 270.

FDA Disqualification of a Clinical Investigator. Sept., p. 498.

FDA Premarket Approval of New Medical Devices: Confidentiality of Data. Oct., p. 576.

FDA Seizure and Injunction Actions: Judicial Means of Protecting the Public Health. Feb., p. 112.

FDA's Standards Policy. May, p. 300.

FDA Trade Secret Procedures and Standards. June, p. 362.

Fleshner, Robert—*Lannett*, Premarketing Clearance and "Me-Too" Drugs: Where Do We Go from Here? Jan., p. 44.

Food and Drug Law

Recent Developments 1979—1980. Sept., p. 527.

Food and Drug Regulation

Transition. May, p. 283.

Food and Drug Regulation in Transition. May, p. 283.

A Food Company's Approach to the Inspectional Process. Aug., p. 436.

Food GMP's. Apr., p. 215.

Food Inspection

A Trade Association View of the FDA Food Inspection Programs. Mar., p. 170.

Food Inspection: The Quest for Objectivity. Mar., p. 149.

Food Inspection: The Quest for Objectivity. Mar., p. 149.

Food Labeling

Food Labeling: More or Better? Mar., p. 160.

Proposal for a Realistic Improvement in the Labeling of Processed Food. Mar., p. 143.

Speech to the Annual Educational Conference of the Food and Drug Law Institute. Apr., p. 188.

Food Labeling: More or Better? Mar., p. 160.

Food Regulation and the New Technology: The Evolving Governmental Process. Jan., p. 15.

Food Regulations
Impact of Sensitivity of Method. June, p. 349.
The U. S. Food and Drug Law: How It Came; How It Works. Mar., p. 132.

Food Safety
Food Regulation and the New Technology: The Evolving Governmental Process. Jan., p. 15.

Ford, Richard A.—The Role and Responsibility of the Monitor Under the GLP Regulation. Nov., p. 620.

Frankel, Robert—IND/NDA Rewrite. May, p. 260.

Freedom of Information
FDA's Policy. Nov., p. 627.
How to Handle an FOI Problem. Dec., p. 668.

Freedom of Information Policy at the FDA. Nov., p. 627.

G

Gardner, Marsha W.—Completing the OTC Process. Dec., p. 698.

Generic Drugs
Lannett, Premarketing Clearance and "Me-Too" Drugs: Where Do We Go from Here? Jan., p. 44.
Law, Power and Money. May, p. 306.
Recent Developments Regarding Look-Alike Drugs. Jan., p. 4.

GLP Regulation
The Role and Responsibility of the Monitor. Nov., p. 620.

Good Manufacturing Practices
Food GMP's. Apr., p. 215.
Remarks. Apr., p. 232.

Gottrich, Ron.—Unapproved New Drugs and State Law. Dec., p. 677.

Goyan, Jere E., Ph.D.—Remarks. Apr., p. 232.

H

Health Protection Branch
Evolution of Drug Regulation in Canada. Aug., p. 451.

History of Premarket Approval Provisions of the Device Amendments. Oct., p. 568.

How to Handle an FOI Problem. Dec., p. 668.

Human Pharmaceuticals, Patents, and the FDA. Feb., p. 83.

Human Test Subjects
The Role of FDA Disqualification of Clinical Investigators. Sept., p. 484.
A View from the Testing Laboratory. Sept., p. 511.

Hutt, Peter Barton—Food and Drug Regulation in Transition. May, p. 283.

Hyman, Paul M.—Old Drug/New Drug: The Marketplace Influences the Law. Apr., p. 221.

I

The Impact of Sensitivity of Method on Food Regulation. June, p. 349.

In Vitro Medical Devices. June, p. 381.

IND/NDA
Rewrite. May, p. 260.

IND/NDA Rewrite. May, p. 260.

Injunctions

FDA Seizure and Injunction Actions: Judicial Means of Protecting the Public Health. Feb., p. 112.

Inspections

Actions in the Courts. Sept., p. 502.

The Constitutionality of Warrantless Inspections by the Food and Drug Administration. Jan., p. 25.

A Food Company's Approach. Aug., p. 436.

Food GMP's. Apr., p. 215.

Food Inspection: The Quest for Objectivity. Mar., p. 149.

Planning Process. Oct., p. 555.

A Trade Association View of the FDA Food Inspection Programs. Mar., p. 170.

The Inspections Process. Oct., p. 555.

J

Jacobs, Jerald A.—FDA Premarket Approval of New Medical Devices: Confidentiality of Data. Oct., p. 576.

Janssen, Wallace F.—The U. S. Food and Drug Law: How It Came; How It Works. Mar., p. 132.

K

Kahan, Jonathan S.—Recent Developments Regarding Look-Alike Drugs. Jan., p. 4.

Khan, Paul—Food Labeling: More or Better? Mar., p. 160.

Korwek, Edward L.—The NIH Guidelines for Recombinant DNA Research and the Authority of FDA to Require Compliance with the Guidelines. Nov., p. 633.

L

Labeling

Comments on "Imitation" Food Cases. Aug., p. 462.

Food Labeling: More or Better? Mar., p. 160.

Food Regulation and the New Technology: The Evolving Governmental Process. Jan., p. 15.

Proposal for a Realistic Improvement in the Labeling of Processed Food. Mar., p. 143.

Restraints on Use of the Tterm "Natural" in Advertising of Foods. July, p. 404.

Speech to the Annual Educational Conference of the Food and Drug Law Institute. Apr., p. 188.

Laetrile

Comments on Recent Cases. Feb., p. 122.

Lambert, Eugene I.—Law, Power & Money: A Generic Trinity. May, p. 306.

Lannett, Premarketing Clearance and "Me-Too" Drugs: Where Do We Go from Here? Jan., p. 44.

Law

Recent Developments 1979—1980. Sept., p. 527.

Law, Power & Money: A Generic Trinity. May, p. 306.

Legislation

Biologics and Government Regulation. June, p. 385.

Lisook, Alan—The New Clinical Investigator Regulations. Sept., p. 493.

Long, James M.—Cosmetic Industry Concerns Arising from Recent FDA Activities. June, p. 392.

Lushbough, Channing H.—A Food Company's Approach to the Inspectional Process. Aug., p. 436.

M

Mahinka, Stephen Paul—The Setting of Standards: Concerns for Medical Device Regulation. May, p. 244.

Maximum Allowable Cost

Lannett, Premarketing Clearance and "Me-Too" Drugs: Where Do We Go from Here? Jan., p. 44.

McGovern, George—Speech to the Annual Educational Conference of the Food and Drug Law Institute. Apr., p. 188.

McNamara, Stephen H.—When Is a Cosmetic Also a Drug—What You Need to Know, and Why. Aug., p. 467.

McNamara, Stephen H.—Preparing for Cosmetic GMP—A Legal Perspective. Nov., p. 651.

Medical Devices

Bureau of Radiological Health. May, p. 314.

Characterization. Oct., p. 588.

Characterization—Another View. Oct., p. 594.

FDA's Advisory Committees: Past and Future. Oct., p. 604.

In Vitro. June, p. 381.

Premarket Approval of New Devices: Confidentiality of Data. Oct., p. 576.

Premarket Approval Procedures. Oct., p. 549.

Premarket Approval Provisions. Oct., p. 568.

The Setting of Standards. May, p. 244.

Medical Privacy

Drug Use Research: Privacy Pitfalls. Apr., p. 235.

Merrill, Richard A.—FDA and the Effects of Substantive Rules. May, p. 270.

Minnich, Charles J.—Protecting Human Test Subjects and the Public: A View from the Testing Laboratory. Sept., p. 511.

Monitors

Role and Responsibility Under the GLP Regulation. Nov., p. 620.

Morey, Richard S.—Characterization of Medical Devices—Another View. Oct., p. 594.

Multi-Source Drugs

Law, Power and Money. May, p. 306.

Munsey, Rodney—New Legislation and Biologics. June, p. 385.

N

NADA

Comments on Recent Cases. Aug., p. 462.

"Natural" Foods

Restraints on Use of the Term in Labeling and Advertising. July, p. 404.

The New Clinical Investigator Regulations. Sept., p. 493.

New Drugs

Unapproved, and State Law. Dec., p. 677.

New Legislation and Biologics. June, p. 385.

Nightingale, Stuart L.—Protecting Human Research Subjects and the Public: The Role of FDA Disqualification of Clinical Investigators. Sept., p. 484.

NIH Guidelines

Recombinant DNA Research and the Authority of FDA to Require Compliance with the Guidelines. Nov., p. 633.

The NIH Guidelines for Recombinant DNA Research and the Authority of FDA to Require Compliance with the Guidelines. Nov., p. 633.

Norcross, Marvin A., V.M.D.—Sensitivity of Method—A Wave of the Future. June, p. 342.

Norton, Deborah B.—The Constitutionality of Warrantless Inspections by the Food and Drug Administration. Jan., p. 25.

O

O'Reilly, James T.—Reading the Tea Leaves: The Past and Future of FDA's Medical Device Advisory Committees. Oct., p. 604.

O'Reilly, James T.—The Role of Corporate Counsel in Defense of FDA Court Actions. June, p. 370.

Old Drug/New Drug: The Marketplace Influences the Law. Apr., p. 221.

Olsson, Philip C.—Food Inspection: The Quest for Objectivity. Mar., p. 149.

Oser, Bernard L.—The Role and Responsibility of the Monitor Under the GLP Regulation. Nov., p. 620.

OTC Review

The Changing Philosophy. Dec., p. 673.

Completing the OTC Process. Dec., p. 698.

Cosmetic or Drug? FDA's OTC Drug Review Program Provides Some Answers and Raises New Questions. Feb., p. 98.

Cosmetics and Labeling. June, p. 325.

The OTC Drug Review—A Change in Direction. Mar., p. 179.

Research as Part of the OTC Review. Dec., p. 684.

The OTC Drug Review—A Change in Direction. Mar., p. 179.

P

Paige, Stephen B.—Critical Devices: Do We Need a New Definition? June, p. 376.

Patent Law

Human Pharmceuticals, Patents, and the FDA. Feb., p. 83.

Phelps, James R.—Actions in the Courts. Sept., p. 502.

Poetsch, Chester E.—Research as Part of the OTC Review. Dec., p. 684.

Premarket Approval

New Medical Devices: Confidentiality of Data. Oct., p. 576.

Procedures for Medical Devices. Oct., p. 549.

Provisions of the Device Amendments. Oct., p. 568.

Premarket Approval Procedures for Medical Devices. Oct., p. 549.

Preparing for Cosmetic GMP—A Legal Perspective. Nov., p. 651.

Proban

Comments on Recent Cases. Feb., p. 122.

Product Liability

1979 Cases—Failure to Warn. July, p. 404.

Product Liability—1979. July, p. 404.

Product Quality

A Food Company's Approach to the Inspectional Process. Aug., p. 436.

Proposal for a Realistic Improvement in the Labeling of Processed Food. Mar., p. 143.

Protecting Human Research Subjects and the Public: The Role of FDA Disqualification of Clinical Investigators. Sept., p. 484.

Protecting Human Test Subjects and the Public: A View from the Testing Laboratory. Sept., p. 511.

Q

Quinn, Taylor M.—Food GMP's. Apr., p. 215.

R

Raubicheck, Charles J.—The OTC Drug Review—A Change in Direction. Mar., p. 179.

Reading the Tea Leaves: The Past and Future of FDA's Medical Device Advisory Committees. Oct., p. 604.

Recent Developments in Food and Drug Law 1979—1980. Sept., p. 527.

Recent Developments Regarding Look-Alike Drugs. Jan., p. 4.

Recombinant DNA

The NIH Guidelines for Recombinant DNA Research and the Authority of FDA to Require Compliance with the Guidelines. Nov., p. 633.

The Regulation of Clinical Investigators. July, p. 415.

Regulations

Clinical Investigators. July, p. 415; Sept., p. 493.

In Vitro Medical Devices. June, p. 381.

Regulatory Reform? Apr., p. 193.

Remarks. Apr., p. 232.

Regulatory Reform

Regulatory Reform? Apr., p. 193.

Regulatory Reform? Apr., p. 193.

Remarks. Apr., p. 232.

Research

The OTC Review. Dec., p. 684.

Research as Part of the OTC Review. Dec., p. 684.

Restraints on Use of the Term "Natural" in Advertising and Labeling of Foods. July, p. 424.

Rogers, Paul G.—Recent Developments Regarding Look-Alike Drugs. Jan., p. 4.

The Role of Corporate Counsel in Defense of FDA Court Actions. June, p. 370.

The Role and Responsibility of the Monitor Under the GLP Regulation. Nov., p. 620.

S

Scarlett, Thomas—Cosmetic Ingredients and Labeling in the OTC Drug Review. June, p. 325.

Schiffmiller, Martin—Human Pharmaceuticals, Patents, and the FDA. Feb., p. 83.

Schultz, Roger A.—The Changing Philosophy of OTC Review. Dec., p. 673.

Seizures

FDA Seizure and Injunction Actions: Judicial Means of Protecting the Public Health. Feb., p. 112.

Sensitivity of Method

Impact on Food Regulation. June, p. 349.

Legal Implications. June, p. 355.

A Wave of the Future. June, p. 342.

Sensitivity of Method—Legal Implications. June, p. 355.

Sensitivity of Method—A Wave of the Future. June, p. 342.

The Setting of Standards: Concerns for Medical Device Regulation. May, p. 244.

Sheridan, Robert L.—Premarket Approval Procedures for Medical Devices. Oct., p. 549.

Speech to the Annual Educational Conference of the Food and Drug Law Institute. Apr., p. 188.

Spence, Greggory Keith—FDA Trade Secret Procedures and Standards. June, p. 362.

Standards-Setting

FDA's policy. May, p. 300.

Medical Device Regulation. May, p. 244.

State Law

Unapproved New Drugs. Dec., p. 677.

Stimson, Richard A., Ph.D.—FDA's Standards Policy. May, p. 300.

Substitution

Recent Developments Regarding Look-Alike Drugs. Jan., p. 4.

T

Testing Laboratory

Protecting Human Test Subjects. Sept., p. 511.

Therapeutic Use of Marihuana and Heroin: The Legal Framework. Feb., p. 68.

Trade Secrets

FDA Procedures and Standards. June, p. 362.

Transition

Food and Drug Regulation. May, p. 283.

The U. S. Food and Drug Law: How It Came; How It Works. Mar., p. 132.

U

Unapproved New Drugs and State Law. Dec., p. 677.

V

Veale, James R.—Characterization of Medical Devices. Oct., p. 588.

Vocci, Frank J.—The Drug Enforcement Administration: Scheduling Policy and Classification. Dec., p. 691.

W

Warrants

The Constitutionality of Warrantless Inspections by the Food and Drug Administration. Jan., p. 25.

Wassenaar, W.—Canada: Evolution of Drug Regulation Within the Health Protection Branch. Aug., p. 451.

Weeda, David F.—FDA Seizure and Injunction Actions: Judicial Means of Protecting the Public Health. Feb., p. 112.

Weitzman, Stephen A. and Cooper, Iver P.—Comments on Recent Cases. Aug., p. 462.

Weitzman, Stephen A.—Comments on Recent Cases. Feb., p. 122.

Wenninger, John A.—Cosmetics—FDA Technical Update. June, p. 335.

When Is a Cosmetic Also a Drug—What You Need to Know, and Why. Aug., p. 467.

Wohlreich, Jack J.—*In Vitro* Medical Devices. June, p. 381.

Y

Youngs, Maynard L.—How to Handle an FOI Problem. Dec., p. 668.